{"id": "article-24605_0", "title": "Lymphoproliferative Disorders -- Continuing Education Activity", "content": "Lymphoproliferative disorders (LPD) comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. These diseases often occur in immunocompromised individuals. There are two subsets of lymphocytes: T and B cells that regenerate uncontrollably to produce immunoproliferative disorders, which are prone to immunodeficiency, a dysfunctional immune system, and lymphocyte dysregulation. Several gene mutations have been described as causes of LPD that can be iatrogenic or acquired. Describe the roles of various interprofessional team members in caring for patients with LPD and how the team can improve chances for survival and recovery.", "contents": "Lymphoproliferative Disorders -- Continuing Education Activity. Lymphoproliferative disorders (LPD) comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. These diseases often occur in immunocompromised individuals. There are two subsets of lymphocytes: T and B cells that regenerate uncontrollably to produce immunoproliferative disorders, which are prone to immunodeficiency, a dysfunctional immune system, and lymphocyte dysregulation. Several gene mutations have been described as causes of LPD that can be iatrogenic or acquired. Describe the roles of various interprofessional team members in caring for patients with LPD and how the team can improve chances for survival and recovery."}
{"id": "article-24605_1", "title": "Lymphoproliferative Disorders -- Continuing Education Activity", "content": "Objectives: Describe the signs and symptoms of lymphoproliferative disorders. Review the diagnostic evaluation of LPD. Explain treatment considerations for patients with LPD. identify the roles of various interprofessional team members in caring for patients with LPD and improving chances for survival and recovery. Access free multiple choice questions on this topic.", "contents": "Lymphoproliferative Disorders -- Continuing Education Activity. Objectives: Describe the signs and symptoms of lymphoproliferative disorders. Review the diagnostic evaluation of LPD. Explain treatment considerations for patients with LPD. identify the roles of various interprofessional team members in caring for patients with LPD and improving chances for survival and recovery. Access free multiple choice questions on this topic."}
{"id": "article-24605_2", "title": "Lymphoproliferative Disorders -- Introduction", "content": "Lymphoproliferative disorders (LPD) [1] [2] comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. These diseases often occur in immunocompromised individuals. There are two subsets of lymphocytes: T and B cells that regenerate uncontrollably to produce immunoproliferative disorders, which are prone to immunodeficiency, a dysfunctional immune system, and lymphocyte dysregulation. Several gene mutations have been described as causes of LPD that can be iatrogenic or acquired.", "contents": "Lymphoproliferative Disorders -- Introduction. Lymphoproliferative disorders (LPD) [1] [2] comprise a heterogeneous group of diseases characterized by uncontrolled production of lymphocytes that cause monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. These diseases often occur in immunocompromised individuals. There are two subsets of lymphocytes: T and B cells that regenerate uncontrollably to produce immunoproliferative disorders, which are prone to immunodeficiency, a dysfunctional immune system, and lymphocyte dysregulation. Several gene mutations have been described as causes of LPD that can be iatrogenic or acquired."}
{"id": "article-24605_3", "title": "Lymphoproliferative Disorders -- Introduction", "content": "The X-linked LPD is characterized by a mutation in the X chromosome that predisposes to natural killer cell LPD and T-cell LPD. Autoimmune lymphoproliferative syndrome (ALPS) is a type of LPD caused by a mutation in the gene that encodes for a Fas protein which is located in the long arm of chromosome 10. Males with X-linked immunodeficiency syndrome are susceptible to LPD and at risk for acquiring EBV and further development of lymphoma.", "contents": "Lymphoproliferative Disorders -- Introduction. The X-linked LPD is characterized by a mutation in the X chromosome that predisposes to natural killer cell LPD and T-cell LPD. Autoimmune lymphoproliferative syndrome (ALPS) is a type of LPD caused by a mutation in the gene that encodes for a Fas protein which is located in the long arm of chromosome 10. Males with X-linked immunodeficiency syndrome are susceptible to LPD and at risk for acquiring EBV and further development of lymphoma."}
{"id": "article-24605_4", "title": "Lymphoproliferative Disorders -- Introduction", "content": "Individuals with common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, ataxia-telangiectasia, Chediak\u2013Higashi syndrome and viral infections including HIV, are also prone to LPD. Others at risk include patients undergoing tissue transplantation and the use of immunosuppressive drugs such as cyclosporin, sirolimus, and tacrolimus. Invasive fungal infections have also been linked to this pathology. [3]", "contents": "Lymphoproliferative Disorders -- Introduction. Individuals with common variable immunodeficiency (CVID), severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, ataxia-telangiectasia, Chediak\u2013Higashi syndrome and viral infections including HIV, are also prone to LPD. Others at risk include patients undergoing tissue transplantation and the use of immunosuppressive drugs such as cyclosporin, sirolimus, and tacrolimus. Invasive fungal infections have also been linked to this pathology. [3]"}
{"id": "article-24605_5", "title": "Lymphoproliferative Disorders -- Introduction", "content": "Chronic lymphoproliferative disorders are immuno-morphologically and clinically heterogeneous. Common features of these processes include various immunophenotypes (T, B, and NK cells) and terminal deoxynucleotidyl transferase negativity. The B-cell lymphocytic disorders include B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, non-Hodgkin lymphoma (including mantle cell lymphoma) in leukemic phase, hairy cell leukemia and splenic lymphoma with villous lymphocytes. The T-cell chronic lymphoproliferative disorders include Sezary syndrome, T-cell prolymphocytic leukemia, adult T-cell leukemia-lymphoma, and large granulated lymphocyte leukemia. [4]", "contents": "Lymphoproliferative Disorders -- Introduction. Chronic lymphoproliferative disorders are immuno-morphologically and clinically heterogeneous. Common features of these processes include various immunophenotypes (T, B, and NK cells) and terminal deoxynucleotidyl transferase negativity. The B-cell lymphocytic disorders include B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, non-Hodgkin lymphoma (including mantle cell lymphoma) in leukemic phase, hairy cell leukemia and splenic lymphoma with villous lymphocytes. The T-cell chronic lymphoproliferative disorders include Sezary syndrome, T-cell prolymphocytic leukemia, adult T-cell leukemia-lymphoma, and large granulated lymphocyte leukemia. [4]"}
{"id": "article-24605_6", "title": "Lymphoproliferative Disorders -- Etiology", "content": "X-linked LPD can present as X-LPD-1 where there is a mutation on the X-chromosome associated with a T- and NK-cell lymphoproliferative disease. The mutation is on the long arm of the X chromosome, at position 25 (Xq25), where there\u00a0is a\u00a0deletion in the SH2D1A gene, which encodes for an SH2 domain\u00a0on SLAM-associated protein (SAP). Recipients of solid organs or allogeneic hematopoietic stem cells are at increased risk of developing lymphoma, which can be secondary to immunosuppression caused by Epstein-Barr virus (EBV). [5]", "contents": "Lymphoproliferative Disorders -- Etiology. X-linked LPD can present as X-LPD-1 where there is a mutation on the X-chromosome associated with a T- and NK-cell lymphoproliferative disease. The mutation is on the long arm of the X chromosome, at position 25 (Xq25), where there\u00a0is a\u00a0deletion in the SH2D1A gene, which encodes for an SH2 domain\u00a0on SLAM-associated protein (SAP). Recipients of solid organs or allogeneic hematopoietic stem cells are at increased risk of developing lymphoma, which can be secondary to immunosuppression caused by Epstein-Barr virus (EBV). [5]"}
{"id": "article-24605_7", "title": "Lymphoproliferative Disorders -- Epidemiology", "content": "LPD is a disease caused by cells of the lymphatic system that grow excessively.\u00a0B-cell neoplasms are much more common than T-cell neoplasms in the United States and Europe.", "contents": "Lymphoproliferative Disorders -- Epidemiology. LPD is a disease caused by cells of the lymphatic system that grow excessively.\u00a0B-cell neoplasms are much more common than T-cell neoplasms in the United States and Europe."}
{"id": "article-24605_8", "title": "Lymphoproliferative Disorders -- Epidemiology", "content": "Epstein-Barr virus (EBV) is an etiological factor for most lymphoproliferative disorders. EBV infects 90% of people during their lives. It presumably spreads by saliva or droplets. It has an incubation period of 4 to 5 weeks. In early childhood, it causes few symptoms, but in adolescents and young adults, it may cause infectious mononucleosis.", "contents": "Lymphoproliferative Disorders -- Epidemiology. Epstein-Barr virus (EBV) is an etiological factor for most lymphoproliferative disorders. EBV infects 90% of people during their lives. It presumably spreads by saliva or droplets. It has an incubation period of 4 to 5 weeks. In early childhood, it causes few symptoms, but in adolescents and young adults, it may cause infectious mononucleosis."}
{"id": "article-24605_9", "title": "Lymphoproliferative Disorders -- Pathophysiology", "content": "Lymphoproliferative disorders originate when physiological mechanisms of control of proliferation of both T and B cells break down, resulting in the uncontrolled and autonomous increase of immune cells leading to lymphocytosis and lymphadenopathy, and often involvement of extranodal sites, e.g., bone marrow.", "contents": "Lymphoproliferative Disorders -- Pathophysiology. Lymphoproliferative disorders originate when physiological mechanisms of control of proliferation of both T and B cells break down, resulting in the uncontrolled and autonomous increase of immune cells leading to lymphocytosis and lymphadenopathy, and often involvement of extranodal sites, e.g., bone marrow."}
{"id": "article-24605_10", "title": "Lymphoproliferative Disorders -- Pathophysiology", "content": "In immunocompromised patients, EBV can cause a mild disease. However, in immune-suppressed transplant patients, immunosurveillance may be compromised by the lack of T cells, leading to a proliferation of EBV-infected B-lymphocytes and post-transplant lymphoproliferative disorder (PTLD). Polyclonal PTLD can form tumor masses and presents with symptoms of a mass effect. Monoclonal forms of PTLD can manifest as a disseminated malignant lymphoma.", "contents": "Lymphoproliferative Disorders -- Pathophysiology. In immunocompromised patients, EBV can cause a mild disease. However, in immune-suppressed transplant patients, immunosurveillance may be compromised by the lack of T cells, leading to a proliferation of EBV-infected B-lymphocytes and post-transplant lymphoproliferative disorder (PTLD). Polyclonal PTLD can form tumor masses and presents with symptoms of a mass effect. Monoclonal forms of PTLD can manifest as a disseminated malignant lymphoma."}
{"id": "article-24605_11", "title": "Lymphoproliferative Disorders -- Histopathology", "content": "Analysis of blood samples frequently reveals large quantities of immature lymphocytes that are usually oligoclonal. One may see monoclonal cell populations in primary malignant tumors other than in LPD. Cytogenetic alterations are uncommon in LPD. Prolymphocytic leukemia is an uncommon variant of chronic lymphocytic leukemia (CLL). It differs from small cell CLL in that the\u00a0leukemic cells are larger with more cytoplasm, and a prominent nucleolus. Approximately two-thirds have the phenotype of B cells.", "contents": "Lymphoproliferative Disorders -- Histopathology. Analysis of blood samples frequently reveals large quantities of immature lymphocytes that are usually oligoclonal. One may see monoclonal cell populations in primary malignant tumors other than in LPD. Cytogenetic alterations are uncommon in LPD. Prolymphocytic leukemia is an uncommon variant of chronic lymphocytic leukemia (CLL). It differs from small cell CLL in that the\u00a0leukemic cells are larger with more cytoplasm, and a prominent nucleolus. Approximately two-thirds have the phenotype of B cells."}
{"id": "article-24605_12", "title": "Lymphoproliferative Disorders -- Histopathology", "content": "Post-transplant lymphoproliferative disorder (PTLD) is a B-lymphocyte growth caused by\u00a0therapeutic immunosuppression\u00a0common after organ transplantation. Patients can develop polyclonal B-cell hyperplasia. The presence of Reed-Sternberg cells can differentiate Hodgkin lymphoma from non-Hodgkin lymphomas.", "contents": "Lymphoproliferative Disorders -- Histopathology. Post-transplant lymphoproliferative disorder (PTLD) is a B-lymphocyte growth caused by\u00a0therapeutic immunosuppression\u00a0common after organ transplantation. Patients can develop polyclonal B-cell hyperplasia. The presence of Reed-Sternberg cells can differentiate Hodgkin lymphoma from non-Hodgkin lymphomas."}
{"id": "article-24605_13", "title": "Lymphoproliferative Disorders -- Toxicokinetics", "content": "Generation of T-cell depletion by use of anti-T lymphocyte antibodies in the prevention/treatment of graft rejection can further increase the risk of developing post-transplant lymphoproliferative disorder (PTLD). Such antibodies include anti-lymphocyte globulin (ALG), muromonab-CD3 (OKT3), and anti-thymocyte globulin (ATG).", "contents": "Lymphoproliferative Disorders -- Toxicokinetics. Generation of T-cell depletion by use of anti-T lymphocyte antibodies in the prevention/treatment of graft rejection can further increase the risk of developing post-transplant lymphoproliferative disorder (PTLD). Such antibodies include anti-lymphocyte globulin (ALG), muromonab-CD3 (OKT3), and anti-thymocyte globulin (ATG)."}
{"id": "article-24605_14", "title": "Lymphoproliferative Disorders -- History and Physical", "content": "The X-linked lymphoproliferative syndrome is characterized by an inappropriate immune response to EBV and leads to death from infectious mononucleosis, a dysgammaglobulinemia, or a B-cell lymphoproliferative disorder. However, the link between X-linked lymphoproliferative disorder and EBV is unknown.", "contents": "Lymphoproliferative Disorders -- History and Physical. The X-linked lymphoproliferative syndrome is characterized by an inappropriate immune response to EBV and leads to death from infectious mononucleosis, a dysgammaglobulinemia, or a B-cell lymphoproliferative disorder. However, the link between X-linked lymphoproliferative disorder and EBV is unknown."}
{"id": "article-24605_15", "title": "Lymphoproliferative Disorders -- History and Physical", "content": "ALPS presents with an increased size of lymphoid organs including lymph nodes and spleen in up to 90% of patients. The liver may be enlarged in up to 40% of patients. Autoimmune cytopenia is common including autoimmune hemolytic anemia, neutropenia, and thrombocytopenia. Symptoms that resemble systemic lupus erythematosus may be present. ALPS is associated with other autoimmune disorders like autoimmune cerebellar ataxia, transverse myelitis, Guillain\u2013Barre syndrome, and autoimmune glomerulonephritis. Clinical features of chronic hematological malignancies (chronic leukemias and lymphomas) include: Males\u00a0are more affected\u00a0than women Asthenia Anemia Thrombocytopenia Granulocytopenia Loss of weight Lymphadenopathy (for example, peripheral, mesenteric, and retroperitoneal). Splenomegaly Hepatomegaly Metastatic\u00a0disease affecting several organs including jaw, liver, ovaries, central nervous\u00a0system (CNS), and gastrointestinal (GI) tract Recurrent infections Skin rash", "contents": "Lymphoproliferative Disorders -- History and Physical. ALPS presents with an increased size of lymphoid organs including lymph nodes and spleen in up to 90% of patients. The liver may be enlarged in up to 40% of patients. Autoimmune cytopenia is common including autoimmune hemolytic anemia, neutropenia, and thrombocytopenia. Symptoms that resemble systemic lupus erythematosus may be present. ALPS is associated with other autoimmune disorders like autoimmune cerebellar ataxia, transverse myelitis, Guillain\u2013Barre syndrome, and autoimmune glomerulonephritis. Clinical features of chronic hematological malignancies (chronic leukemias and lymphomas) include: Males\u00a0are more affected\u00a0than women Asthenia Anemia Thrombocytopenia Granulocytopenia Loss of weight Lymphadenopathy (for example, peripheral, mesenteric, and retroperitoneal). Splenomegaly Hepatomegaly Metastatic\u00a0disease affecting several organs including jaw, liver, ovaries, central nervous\u00a0system (CNS), and gastrointestinal (GI) tract Recurrent infections Skin rash"}
{"id": "article-24605_16", "title": "Lymphoproliferative Disorders -- Evaluation", "content": "The new criteria required for the diagnosis of an autoimmune lymphoproliferative syndrome (ALPS) [6] include chronic non-malignant lymphoproliferation (lymphadenopathy or splenomegaly over six months of evolution) and elevated peripheral blood double-negative T cells (DNTs). The first accessory in diagnosis is a somatic or a germ-line mutation in ALPS causative gene ( FASL , CASP10 , FAS ) and defective in vitro Fas-mediated apoptosis. Secondary diagnostic criteria are elevated biomarkers (plasma sFASL over 200 pg/ml, plasma or serum vitamin B12 greater than 1500 ng/L, plasma IL-10 greater than 20 pg/ml, and plasma IL-18 greater than 500pg/ml) and immunohistochemical findings on biopsy consistent with ALPS. Other diagnostic signs are polyclonal hypergammaglobulinemia, autoimmune cytopenia and a family history of ALPS or non-malignant lymphoproliferation.", "contents": "Lymphoproliferative Disorders -- Evaluation. The new criteria required for the diagnosis of an autoimmune lymphoproliferative syndrome (ALPS) [6] include chronic non-malignant lymphoproliferation (lymphadenopathy or splenomegaly over six months of evolution) and elevated peripheral blood double-negative T cells (DNTs). The first accessory in diagnosis is a somatic or a germ-line mutation in ALPS causative gene ( FASL , CASP10 , FAS ) and defective in vitro Fas-mediated apoptosis. Secondary diagnostic criteria are elevated biomarkers (plasma sFASL over 200 pg/ml, plasma or serum vitamin B12 greater than 1500 ng/L, plasma IL-10 greater than 20 pg/ml, and plasma IL-18 greater than 500pg/ml) and immunohistochemical findings on biopsy consistent with ALPS. Other diagnostic signs are polyclonal hypergammaglobulinemia, autoimmune cytopenia and a family history of ALPS or non-malignant lymphoproliferation."}
{"id": "article-24605_17", "title": "Lymphoproliferative Disorders -- Treatment / Management", "content": "Epstein\u2013Barr virus (EBV)-associated T-cell\u00a0and/or NK-cell (EBV\u00a0T/NK-cell) lymphoproliferative disorders can\u00a0be cured in most cases with allogeneic hematopoietic stem cell transplantation (HSCT). Primary-EBV infection-associated hemophagocytic lymphohistiocytosis\u00a0that is an EBV\u00a0T/NK-cell lymphoproliferation may be managed with the use of steroids, cyclosporine A, and etoposide. Remission is known to occur in some patients but may require\u00a0multi-drug block chemotherapy. [2]", "contents": "Lymphoproliferative Disorders -- Treatment / Management. Epstein\u2013Barr virus (EBV)-associated T-cell\u00a0and/or NK-cell (EBV\u00a0T/NK-cell) lymphoproliferative disorders can\u00a0be cured in most cases with allogeneic hematopoietic stem cell transplantation (HSCT). Primary-EBV infection-associated hemophagocytic lymphohistiocytosis\u00a0that is an EBV\u00a0T/NK-cell lymphoproliferation may be managed with the use of steroids, cyclosporine A, and etoposide. Remission is known to occur in some patients but may require\u00a0multi-drug block chemotherapy. [2]"}
{"id": "article-24605_18", "title": "Lymphoproliferative Disorders -- Treatment / Management", "content": "In autoimmune lymphoproliferative syndrome, one should treat the underlying autoimmune disease. First-line therapy includes the use of corticosteroids and intravenous immunoglobulins. Second-line treatment includes mycophenolate\u00a0mofetil. Sirolimus, which is a mammalian target of rapamycin (mTOR) can lead to near-complete resolution of\u00a0the autoimmune disease. [7]", "contents": "Lymphoproliferative Disorders -- Treatment / Management. In autoimmune lymphoproliferative syndrome, one should treat the underlying autoimmune disease. First-line therapy includes the use of corticosteroids and intravenous immunoglobulins. Second-line treatment includes mycophenolate\u00a0mofetil. Sirolimus, which is a mammalian target of rapamycin (mTOR) can lead to near-complete resolution of\u00a0the autoimmune disease. [7]"}
{"id": "article-24605_19", "title": "Lymphoproliferative Disorders -- Treatment / Management", "content": "PTLD can spontaneously regress with cessation or reduction of immunosuppressant therapy and can additionally be treated with antiviral therapy. One can also treat hematological malignancies with multiple-agent chemotherapy, including\u00a0cyclophosphamide\u00a0and prednisone in combination with vincristine and doxorubicin. Rituximab\u00a0has been used to treat CD20-positive hematological malignancies since 1997 and now can be replaced by anti-CD20 biosimilar that is more\u00a0effective. [8]", "contents": "Lymphoproliferative Disorders -- Treatment / Management. PTLD can spontaneously regress with cessation or reduction of immunosuppressant therapy and can additionally be treated with antiviral therapy. One can also treat hematological malignancies with multiple-agent chemotherapy, including\u00a0cyclophosphamide\u00a0and prednisone in combination with vincristine and doxorubicin. Rituximab\u00a0has been used to treat CD20-positive hematological malignancies since 1997 and now can be replaced by anti-CD20 biosimilar that is more\u00a0effective. [8]"}
{"id": "article-24605_20", "title": "Lymphoproliferative Disorders -- Differential Diagnosis", "content": "EBV is\u00a0associated with various cancers including lymphoma and infectious mononucleosis that can mimic lymphoproliferative syndrome/disorders. Multiple myelomas are a monoclonal proliferation of a clone of plasma cells. The clinical syndrome of multiple myeloma is characterized by hypergammaglobulinemia, hypercalcemia, susceptibility to infections, and pathological fractures.", "contents": "Lymphoproliferative Disorders -- Differential Diagnosis. EBV is\u00a0associated with various cancers including lymphoma and infectious mononucleosis that can mimic lymphoproliferative syndrome/disorders. Multiple myelomas are a monoclonal proliferation of a clone of plasma cells. The clinical syndrome of multiple myeloma is characterized by hypergammaglobulinemia, hypercalcemia, susceptibility to infections, and pathological fractures."}
{"id": "article-24605_21", "title": "Lymphoproliferative Disorders -- Radiation Oncology", "content": "Radiation therapy can be used in the treatment of Hodgkin lymphoma as it plays a vital role in localized disease. It is beneficial when combined with chemotherapy in high-grade lymphoma and may be the choice of treatment for low-grade lymphomas. [9] [10]", "contents": "Lymphoproliferative Disorders -- Radiation Oncology. Radiation therapy can be used in the treatment of Hodgkin lymphoma as it plays a vital role in localized disease. It is beneficial when combined with chemotherapy in high-grade lymphoma and may be the choice of treatment for low-grade lymphomas. [9] [10]"}
{"id": "article-24605_22", "title": "Lymphoproliferative Disorders -- Pertinent Studies and Ongoing Trials", "content": "A study (phase 2) of adoptively transferred EBV-specific T lymphocytes showed\u00a0high efficacy with minimal toxicity in patients with EBV-positive post-transplantation lymphoproliferative disease. [11]", "contents": "Lymphoproliferative Disorders -- Pertinent Studies and Ongoing Trials. A study (phase 2) of adoptively transferred EBV-specific T lymphocytes showed\u00a0high efficacy with minimal toxicity in patients with EBV-positive post-transplantation lymphoproliferative disease. [11]"}
{"id": "article-24605_23", "title": "Lymphoproliferative Disorders -- Prognosis", "content": "Overall, the disorder has\u00a0a poor outcome, but myeloablative hematopoietic stem cell transplantation (SCT) may be beneficial in some patients. [12]", "contents": "Lymphoproliferative Disorders -- Prognosis. Overall, the disorder has\u00a0a poor outcome, but myeloablative hematopoietic stem cell transplantation (SCT) may be beneficial in some patients. [12]"}
{"id": "article-24605_24", "title": "Lymphoproliferative Disorders -- Complications", "content": "Lymphoproliferative disease (LPD) is a recognized complication of\u00a0immune dysregulation syndromes and primary immunodeficiency (PID). The recurrent lymphoproliferative disease is a post-transfusional complication. [12] PTLD may sometimes\u00a0progress to non-Hodgkin lymphoma that\u00a0can often be fatal.", "contents": "Lymphoproliferative Disorders -- Complications. Lymphoproliferative disease (LPD) is a recognized complication of\u00a0immune dysregulation syndromes and primary immunodeficiency (PID). The recurrent lymphoproliferative disease is a post-transfusional complication. [12] PTLD may sometimes\u00a0progress to non-Hodgkin lymphoma that\u00a0can often be fatal."}
{"id": "article-24605_25", "title": "Lymphoproliferative Disorders -- Enhancing Healthcare Team Outcomes", "content": "An interprofessional team should educate and manage the patient with LPD. Since this condition may often be life-threatening, the health care providers should advise the patient or parents entirely about all other treatment options including the use of immunosuppressant therapy, in an already immunocompromised host, and also provide psychological support.", "contents": "Lymphoproliferative Disorders -- Enhancing Healthcare Team Outcomes. An interprofessional team should educate and manage the patient with LPD. Since this condition may often be life-threatening, the health care providers should advise the patient or parents entirely about all other treatment options including the use of immunosuppressant therapy, in an already immunocompromised host, and also provide psychological support."}
{"id": "article-24605_26", "title": "Lymphoproliferative Disorders -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Lymphoproliferative Disorders -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}